PMID- 16206181
OWN - NLM
STAT- MEDLINE
DCOM- 20060118
LR  - 20181201
IS  - 0887-4476 (Print)
IS  - 0887-4476 (Linking)
VI  - 58
IP  - 4
DP  - 2005 Dec 15
TI  - 3,4-Methylenedioxymethamphetamine (MDMA) enhances the release of acetylcholine by 
      5-HT4 and D1 receptor mechanisms in the rat prefrontal cortex.
PG  - 229-35
AB  - 3,4-Methylenedioxymethamphetamine (MDMA), an amphetamine analog, has been shown 
      recently to increase the release of acetylcholine (ACh) in the prefrontal cortex 
      (PFC). The present study further characterizes the stimulatory effect of MDMA on 
      cortical ACh release and examines the role of serotonin (5-HT) and dopamine (DA) 
      receptors in this response. The extracellular concentration of ACh was increased 
      dose-dependently and similarly by the (+) and (-) enantiomers of MDMA (5 and 20 
      mg/kg, i.p.). The systemic administration of the 5-HT(4) antagonist SDZ 205,557 
      (1 mg/kg, i.p.), but not the 5-HT(2A/2B/2C) antagonist LY-53,857 (3 mg/kg, i.p.), 
      significantly decreased cortical ACh release induced by MDMA. The MDMA-induced 
      increase in the extracellular concentration of ACh also was significantly blunted 
      in rats treated with the D(1) receptor antagonist SCH 23390 (0.5 mg/kg, i.p.). 
      The extent to which the coadministration of SDZ 205,557 and SCH 23390 suppressed 
      the MDMA-induced release of ACh in the PFC was no greater than that produced by 
      either antagonist alone. These results suggest that the 5-HT(4) and D(1) receptor 
      subtypes contribute to the mechanism by which MDMA increases ACh release in the 
      PFC.
CI  - Copyright 2005 Wiley-Liss, Inc.
FAU - Nair, Sunila G
AU  - Nair SG
AD  - College of Pharmacy, University of Cincinnati, OH 45267, USA.
FAU - Gudelsky, Gary A
AU  - Gudelsky GA
LA  - eng
GR  - DA 07427/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Synapse
JT  - Synapse (New York, N.Y.)
JID - 8806914
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Ergolines)
RN  - 0 (Hallucinogens)
RN  - 0 (Receptors, Dopamine D1)
RN  - 0 (Serotonin Antagonists)
RN  - 0 (para-Aminobenzoates)
RN  - 137196-67-9 (2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester)
RN  - 158165-40-3 (Receptors, Serotonin, 5-HT4)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - L37TVX7U5M (LY 53857)
RN  - N9YNS0M02X (Acetylcholine)
RN  - TL2TJE8QTX (4-Aminobenzoic Acid)
SB  - IM
MH  - 4-Aminobenzoic Acid/pharmacology
MH  - Acetylcholine/*metabolism
MH  - Animals
MH  - Dopamine Antagonists/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Ergolines/pharmacology
MH  - Hallucinogens/*pharmacology
MH  - Male
MH  - Microdialysis
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Prefrontal Cortex/drug effects/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Dopamine D1/drug effects/*metabolism
MH  - Receptors, Serotonin, 5-HT4/drug effects/*metabolism
MH  - Serotonin Antagonists/pharmacology
MH  - para-Aminobenzoates
EDAT- 2005/10/06 09:00
MHDA- 2006/01/19 09:00
CRDT- 2005/10/06 09:00
PHST- 2005/10/06 09:00 [pubmed]
PHST- 2006/01/19 09:00 [medline]
PHST- 2005/10/06 09:00 [entrez]
AID - 10.1002/syn.20202 [doi]
PST - ppublish
SO  - Synapse. 2005 Dec 15;58(4):229-35. doi: 10.1002/syn.20202.